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• Clozapine decreases, while ziprasidone increases free albumin-SH fraction in rats. 16 
• In vitro drug effects on HSA-SH level/reactivity depend on stearic acid content.   17 




Antipsychotic drugs interfere with the antioxidant defense system provoking complex and often 20 
toxicological effects. Here we examined differences in plasma albumin reduced free thiol (SH) 21 
group content and its reactivity as a consequence of clozapine (CLZ) and ziprasidone (ZIP) 22 
binding. Chronic administration of CLZ reduced, whereas treatment with ZIP increased albumin-23 
SH content in rats. Regardless of the ratio of stearic acid (SA) bound to protein, in vitro binding 24 
of ZIP to human serum albumin (HSA) increased both the SH group level and reactivity. In 25 
contrast, the effect of CLZ on HSA-SH reactivity was dependent on HSA to SA molar ratio. 26 
CLZ binding was accompanied by an increase in HSA-SH reactivity in samples with normal, but 27 
a reduction of its reactivity level with higher SA/HSA ratio, compared to drug-free samples. We 28 
demonstrate by steady-state fluorescence quenching studies that an increase in SA binding to 29 
HSA is associated with a significant reduction of binding constant for both antipsychotics. In 30 
addition, this is the first report of quantitative characterization of ZIP binding to HSA. Our 31 
findings suggest that albumin-SH content and reactivity is modulated by ZIP towards an 32 
increased antioxidant defense capacity in circulation, as opposed to CLZ, which can contribute to 33 
the safer, more effective treatment of schizophrenia.  34 
Keywords: albumin, clozapine, ziprasidone, thiols. 35 
Abbreviations and acronyms: CLZ, Clozapine; ZIP, Ziprasidone; FA(s), Fatty acid(s); HSA, 36 
Human serum albumin; HSA-SH, free thiol in the Cys34 residue of HSA; SA, Stearic acid; 37 
HSA/SA, HSA in complex with SA; HSA/CLZ and HSA/ZIP, HSA in complex with CLZ and 38 
ZIP, respectively; DMSO, Dimethyl sulfoxide; DTNB, 5,5′-Dithiobis-(2-nitrobenzoic acid). 39 
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1. Introduction 40 
Schizophrenia is one of the most common mental disorders that occurs in 1% of the 41 
population and can manifest in a variety of ways and with different symptoms [1]. Although the 42 
disbalance of neurotransmitters turnover plays a central role in the development of schizophrenia 43 
[2], recent studies emphasize the role of reactive oxygen species, oxidative stress and the 44 
accompanying oxidative damage in its pathogenesis [3,4]. The content of small non-protein 45 
antioxidants such as uric acid, bilirubin, and glutathione is found to be consistently lower in 46 
untreated schizophrenic patients compared to healthy controls [5−8].  47 
Due to its high concentration in the circulation, human serum albumin (HSA) accounts 48 
for a major part of the antioxidant capacity of human plasma by binding and carrying radical 49 
scavengers, or by sequestering redox-active transition metal ions [9]. In healthy adults, about 50 
two-thirds of a free thiol group in the Cys34 residue (HSA-SH) on the surface of the protein 51 
exists is a reduced form, constituting the major extracellular source of reactive free thiols [10]. 52 
HSA serves as the primary binding protein for unesterified fatty acids (FAs) in the blood, with 53 
seven asymmetrically arranged binding sites of different affinities for long-chain FAs [11,12]. 54 
Under physiological conditions, circulating HSA carries only one or two FA molecules and this 55 
number increases up to six in the certain disease states [13]. There are two canonical high-56 
affinity sites on HSA (Sudlow I and Sudlow II) for binding and transport of lipophilic drugs. 57 
Anionic heterocyclic compounds primarily bind to the Sudlow I site located in subdomain IIA of 58 
HSA, and aromatic structures preferentially bind to Sudlow II site in subdomain IIIA [12]. There 59 
is increasing evidence in support of the existence of the third major drug binding region of HSA 60 
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within subdomain IB, which accommodates a variety of acidic, neutral, and basic molecules 61 
[14]. 62 
The increased content of plasma FAs is frequently found in schizophrenia [15,16], and 63 
antipsychotic drugs treatment seems to contribute to a decrease in reactive free thiols antioxidant 64 
capacity of plasma [7]. The purpose of this study was to establish whether long-term (4 weeks) 65 
administration of high doses (corresponding to maximal therapeutic doses used for humans) of 66 
two regularly used lipophilic antipsychotic drugs, clozapine (CLZ) and ziprasidone (ZIP) (Fig. 67 
1), influences the level of total thiols and the albumin-SH group in rat plasma. In addition, the 68 
influence of CLZ and ZIP binding to HSA [defatted or in complexes with stearic acid (SA)] on 69 
the HSA-SH content and reactivity were investigated in vitro, followed by characterization of 70 
CLZ and ZIP binding to HSA under identical, controlled physiological conditions. 71 
Figure 1 here (single column) 72 
2. Materials and methods 73 
2.1. Chemicals and reagents 74 
All chemicals of analytical reagent grade were purchased from Sigma-Aldrich Chemie 75 
(Germany) and Merck (Germany) unless otherwise noted. The 20% solution of HSA (96% 76 
purity, intended for clinical use, containing 0.42 M of SH-groups per M of HSA) was purchased 77 
from Baxter (Austria). Bromocresol green albumin assay kit was purchased from Human 78 
(Germany). SA was purchased from Sigma-Aldrich Chemie (Germany). Antipsychotic 79 
medications (Zeldox® and Clozapine) and its active ingredients (ZIP and CLZ) were provided by 80 
Pfizer (Austria) and Remedica Ltd (Cyprus), respectively. 81 
5 
 
2.2. Treatment of rats with antipsychotics 82 
Wistar male albino rats (3 months old, weighing 320-350 g) were kept under standard 83 
conditions at a temperature of 22°C, at a twelve-hour cycle shift of day and night. Implemented 84 
procedures were in accordance with Directive 2010/63/EU concerning the protection of animals 85 
for experimental and other scientific purposes. The study design was approved by the Ethical 86 
Committee for the use of lab animals at the Institute for Biological Research "Siniša Stanković", 87 
University of Belgrade, Serbia. Rats were randomly divided into three groups, with 8 animals per 88 
group. Two groups of animals were treated with drugs (1 mL/kg/day), the first with ZIP (20 89 
mg/mL) and the second with CLZ (45 mg/mL), and control group with drinking water (1 90 
mL/kg/day) for 4 weeks [17]. Applied antipsychotic doses correspond to maximal therapeutic 91 
doses for humans [18]. Drugs were prepared (water suspension of pulverized tablets) and 92 
administered daily in the morning via a gastric tube to ensure that no drug loss occurred. 93 
2.3. Isolation of plasma and albumin from rat blood  94 
In order to avoid the influence of anesthetics binding to plasma albumin [12], rats were 95 
sacrificed by decapitation at 28 days of treatment (following an overnight fast). Blood from the 96 
abdominal aorta was collected in a tube with an anticoagulant (disodium EDTA). Erythrocytes 97 
and the buffy coat were precipitated by centrifugation at 5000 x g for 10 min at a temperature of 98 
10 °C. The supernatant plasma was immediately separated, frozen and stored at -80 °C until 99 
used.  100 
Plasma albumin was isolated by two-step fractional precipitation with saturated 101 
ammonium sulfate solution pH 7.4 [19]. A stock solution of obtained albumin (94% purity) for 102 
further analysis was prepared in 0.1 M sodium phosphate buffer pH 7.4. 103 
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2.4 Analysis of biochemical parameters in rat plasma  104 
A biuret method [20] was used for the quantification of total plasma proteins. To measure 105 
plasma albumin concentration, bromocresol green method was applied [21].  106 
2.5. Preparation of defatted HSA and HSA/SA samples  107 
For in vitro experiments, the commercial HSA was firstly defatted by charcoal method 108 
[22], and optionally, its SH-group was then reduced with dithiothreitol [23]. Working defatted 109 
HSA sample with normal physiological content of the free thiol group (about 70%) was prepared 110 
by mixing appropriate volumes of defatted HSA and reduced defatted HSA solutions. Protein 111 
complexes (HSA/SA samples) with bound SA in molar ratios (protein to FA) of 1:1, 1:2, 1:3 and 112 
1:4 were prepared by mixing the appropriate volumes of 50 mM SA in 99% ethanol and 0.25 113 
mM defatted HSA in 0.1 M sodium phosphate buffer, pH 7.4. 114 
2.6. Preparation of defatted HSA or HSA/SA samples with antipsychotics 115 
Appropriate volumes of CLZ or ZIP stock solutions (25 mM in DMSO) were added to 116 
defatted HSA sample and all HSA/SA samples to get a final protein to drug molar ratio of 1:0.5, 117 
1:1.5, and/or 1:2. Resulted mixtures (various HSA/CLZ, HSA/ZIP, HSA/SA/CLZ or 118 
HSA/SA/ZIP samples) were incubated at 37°C for one hour before further analysis. 119 
2.7. Thiol(s) quantification 120 
The content of total (protein and non-protein) thiols in rat plasma, thiol (SH-group) 121 
content in albumin isolated from rat plasma and in all in vitro HSA samples was determined by a 122 
modified Ellman method, using DTNB (5,5’-dithiobis-(2-nitrobenzoic acid)) reagent [24]. The 123 
obtained values were expressed in mM (plasma) and M -SH/M protein (albumin or HSA). For 124 
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the purpose of relative data comparison, thiol contents in control (defatted) HSA samples were 125 
normalized to 100%. 126 
2.8. Determination of HSA-SH group reactivity 127 
For determination of the pseudo-first-order rate constant (k') as a measure of HSA-SH 128 
reactivity, the amount of DTNB in the reaction HSA mixtures was forty-fold times greater than 129 
the total free thiol groups. Reaction kinetics were monitored spectrophotometrically using the 130 
protocol described in detail elsewhere [25]. Values of k′ (s-1) were determined by fitting the 131 
natural logarithm of unreacted thiol group concentrations vs. time using the linear least squares 132 
model.  133 
2.9. Examination of CLZ and ZIP binding to defatted HSA and HSA/SA samples   134 
Fluorescence spectroscopy was used to characterize/compare the binding of SA and/or 135 
antipsychotics in various defined ratios to standardize (in terms of reduced thiol Cys34 content) 136 
HSA. Working HSA and HSA/SA solutions (Section 2.5.) were prepared on a daily basis, by 137 
diluting the stock solution of HSA with 0.1 M sodium phosphate buffer pH 7.4, and drugs' stocks 138 
with DMSO. Small aliquots of 200 μM CLZ/ZIP solutions were added to 2.5 mL of 1 μM HSA 139 
sample solutions, so that the final concentrations of the ligand were 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 140 
3.5, 4.0 and 4.5 μM. HSA fluorescence spectra were recorded on the FluoroMax-4 Jobin Yvon 141 
(Japan) spectrofluorometer in the 1 cm quartz cell at 37°C. The excitation wavelength was fixed 142 
at 295 nm (excitation of the Trp214 residue in the subdomain IIA), and the emission spectra 143 
were read at 305 to 420 nm, with 4.5 nm slit widths. The final spectra were presented as the 144 
mean value of two accumulations after appropriate blank (buffer and drugs) corrections.  145 
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Fluorescence intensities were corrected for the absorption of excited light and the re-146 
absorption of emitted light (the inner-filter effect) according to the equation [26]: 147 
Fc = Fm 10
(Aex +Aem)/2 148 
where Fm is measured fluorescence, Fc is corrected fluorescence, and Aex and Aem are the 149 
absorbance values of the quencher measured at the excitation and peak emission (340 nm) 150 
wavelength, respectively. 151 
The quenching Stern-Volmer's (SV) constants of HSA complexes containing CLZ/ZIP 152 
were determined using equation [27]: 153 
F0/F = 1+ kq τ0 [Q] = 1 + KSV [Q] 154 
where F0 and F are protein emission fluorescence at 340 nm before and after the addition of the 155 
quencher (CLZ/ZIP), respectively, Ksv is SV quenching constant, kq stands for the biomolecule 156 
fluorescence quenching rate constant, τ0 is the average lifetime of the biomolecule without 157 
quencher (10-8 s) and [Q] is the total quencher concentration. 158 
Estimations of the association (binding) constant (Ka) and a number of binding sites (n) 159 
of CLZ/ZIP on HSA samples were done using equation [28]: 160 
log (F0 - F)/F = - n log(1/([L] - [P] x (F0 - F) /F0) + n logKa 161 
where [L] and [P] are the total concentration of ligand (CLZ/ZIP) and protein (HSA) samples, 162 
respectively. 163 
2.10. Statistical analysis  164 
Each assay was performed in triplicate. The results are expressed as mean ± standard 165 
deviation (S.D.). All statistical analysis and graphical representations of data were performed 166 
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using the Origin Lab 8.0 (Origin Corporation, USA). A probability level of P<0.05 was 167 
considered statistically significant. 168 
3. Results  169 
3.1. Effects of CLZ and ZIP treatment on the total plasma thiols and albumin-SH levels in rats 170 
After 28 days of treatment of rats with antipsychotics (Section 2.2.), total plasma protein 171 
and albumin concentrations were significantly lower (P<0.05) in comparison with the control 172 
group. CLZ produces a significant (P<0.05) reduction in both total plasma thiols (42%) and 173 
albumin-SH content (21%) compared with controls. ZIP treatment caused a small but significant 174 
(P<0.05) increase (13%) of the albumin-SH group level and had no significant effect on total 175 
plasma thiol levels (Table 1).  176 
Table 1 here 177 
3.2. Influence of CLZ or ZIP binding on the HSA-SH content and reactivity in vitro 178 
The influence of CLZ/ZIP binding on the HSA-SH content/reactivity was investigated 179 
following one-hour incubation of defatted HSA sample or HSA/SA complexes with CLZ or ZIP 180 
(Section 2.6.) Regardless of the protein to drug molar ratio and SA content, the binding of CLZ 181 
does not affect the HSA-SH level (Fig. 2, left panel). However, the binding of ZIP to HSA/SA 182 
complexes leads to a small but significant increase (P<0.05) (up to 20%) in the HSA-SH level, 183 
which correlates with the increasing FA and drug content in HSA-complexes (Fig. 2, right 184 
panel).  185 
Figure 2 here (2-column fitting image) 186 
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The examination of HSA-SH reactivity changes upon CLZ/ZIP binding to defatted HSA 187 
sample and HSA/SA complexes was performed by determining the rate constant (k') for protein-188 
free thiol group (Cys34) reaction with DTNB (Section 2.8.). Graphics obtained after the data 189 
linearization show that all reaction samples followed pseudo-first-order reaction kinetics (Fig. 3). 190 
Figure 3 here (2-column fitting image) 191 
The effect of CLZ binding on HSA-SH reactivity was found to be dependent on SA 192 
content. In comparison with complexes without CLZ, in defatted HSA sample and HSA/SA 193 
complexes with normal FA to protein molar ratio (1:1 and 2:1), an increase in the HSA-SH 194 
reactivity which correlates with increased CLZ content was observed (Table 2). In contrast, a 195 
significant decrease (P<0.05) in the HSA-SH reactivity towards DTNB was measured in all 196 
HSA/SA/CLZ complexes containing an increased FA to protein molar ratio (3:1 and 4:1) (Table 197 
2; Fig. 4, left panel).  198 
Table 2 here 199 
Figure 4 here (2-column fitting image) 200 
In all examined drug to protein molar ratios, binding of ZIP to either defatted HSA or 201 
HSA/SA samples significantly increases (up to 62%) HSA-SH reactivity and this effect is SA-202 
content independent (Table 2). Interestingly, the largest single change in reactivity is observed in 203 
defatted HSA/ZIP complexes (Fig. 4, right panel).  204 
3.3. Characterization of CLZ and ZIP binding to defatted HSA and HSA/SA samples 205 
A steady-state fluorescence study has been performed to gain insight into the differences 206 
in binding of antipsychotics to albumin with different SA content. As expected, the binding of 207 
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CLZ and ZIP to HSA is followed by a reduction in the intensity of the HSA emission peak in 208 
comparison to the corresponding defatted HSA and HSA/SA samples (Supplementary Fig. S1). 209 
The quenching of intrinsic protein fluorescence (dominantly originating from Trp214 210 
fluorophore) is higher in complexes with CLZ than ZIP (Fig. 5). 211 
Figure 5 here (2-column fitting image) 212 
The parameters of CLZ or ZIP binding to defatted HSA and HSA/SA samples (protein to 213 
FA molar ratios from 1:1 to 1:4) are calculated (Section 2.9.) and the results are shown in Table 214 
3. The obtained SV plots were linear and Ksv values are calculated from the slope of the curves 215 
F0/F versus [Q] (Supplementary Fig. S2). Quenching rate constant values (1.02−2.89×10
12 216 
M−1s−1) are higher than the limiting diffusion rate constant of the biomolecule (∼1010 M−1s−1), 217 
indicating a static type of quenching [29]. The binding site numbers (n) were obtained from the 218 
slope of the curves log (F0–F)/F vs. log(1/([L]–[P] x (F0–F)/F0) and Ka values are calculated from 219 
the intercept (intercept = n logKa) (Supplementary Fig. S3). The drugs Ka values ranged from 220 
0.25 to 1.90×104 M−1. The highest association constants (CLZ: 1.90 × 104 M−1 and ZIP: 0.95 × 221 
104 M−1) were obtained for defatted HSA-drug complexes. With an increased content of SA in 222 
protein complexes, Ka values for CLZ and ZIP binding decreases, particularly for ZIP (Table 3). 223 
Following the same trend, the estimated number of HSA-drug binding sites is reduced as well, 224 
from 0.792 to 0.592 for CLZ and from 0.786 to 0.545 for ZIP.  225 
4. Discussion 226 
In addition to genetic and environmental factors, the role of oxidative stress in 227 
schizophrenia is an important determinant in pathogenesis and progression of the disease [30,31]. 228 
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There is an increasing number of reports concerning the side effects of atypical antipsychotic 229 
drugs therapy on body redox and antioxidants homeostasis. Reduction in total proteins and 230 
plasma albumin contents observed after 4-week treatment of rats with CLZ and ZIP in this study 231 
indicates that adaptive changes during therapy with these drugs are directed more toward 232 
fulfilling cellular energy demands at the expense of the maintenance of overall cytosolic 233 
composition [32]. We found that treatment of rats with high doses of CLZ, but not with ZIP, 234 
reduced total plasma thiols compared to the values observed in control animals. In addition, CLZ 235 
treatment decreased plasma albumin-SH content. In contrast to CLZ, ZIP treatment increased 236 
rat's albumin-SH group content. The total level of reactive thiols, especially from the albumin, is 237 
an important determinant of overall plasma antioxidant capacity. Relatively well-preserved total 238 
thiol plasma content after the application of ZIP could be a consequence of an increase in 239 
albumin-SH group level. Our findings confirm the influence of chronic antipsychotics drug 240 
treatment on the plasma antioxidant homeostasis [7], pointing to the adverse effects of CLZ 241 
administration in this regard. 242 
An increase in HSA-SH reactivity was detected upon protein interactions with aromatic 243 
compounds (enterolactone and enterodiol) and this effect is found to be SA-dependent [33]. In 244 
addition, it was found that polarity changes in the HSA-SH environment during FAs binding 245 
increased the reactivity of the HSA-SH group [25,34]. We have assumed that binding of CLZ 246 
(tricyclic dibenzodiazepine) and ZIP (benzothiazolylpiperazine derivative) to HSA could 247 
influence the accessibility/content of the Cys34 thiol group on the protein surface and, therefore, 248 
lead to changes in its reactivity/antioxidant capacity. Given the fact that binding sites of 249 
antipsychotics and FAs on HSA overlap [12] and that FAs themselves modulate the reactivity of 250 
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the thiol of HSA [35], their competitive/cooperative interactions were investigated in vitro using 251 
physiologically relevant models with protein to SA molar ratios characteristic for both normal 252 
(1:1 and 1:2) and pathological (1:3 and 1:4) conditions. Binding of CLZ to defatted HSA and 253 
HSA/SA samples in all protein to drug molar ratios (1:0.5, 1:1.5 and 1:2) did not affect HSA-SH 254 
content. On the contrary, binding of ZIP, in general, increased the HSA-SH content. This in vitro 255 
ZIP effect is more pronounced in HSA samples containing more bound ZIP and SA, and is in 256 
agreement with results from in vivo study, where chronic ZIP treatment lead to a beneficial 257 
increase in the albumin-SH content in rats.  258 
Differences in the HSA-SH content and/or reactivity in HSA/SA samples upon 259 
antipsychotics binding likely represent the consequence of their different binding properties. It 260 
has been shown that ZIP and CLZ bind to different sites on the HSA molecule. The binding site 261 
for ZIP is located in the IB region near to critical Cys34 residue [14], while CLZ binds to the 262 
Sudlow I binding site near to critical Trp214 [36]. Only CLZ binding to HSA/SA samples with 263 
physiological FA content led to an increase in the HSA-SH reactivity when compared to drug-264 
free control samples, while increased SA content actually reduced it. In contrast, binding of ZIP 265 
consistently increased thiol group reactivity in all HSA/SA samples compared to control ones. It 266 
should be noticed that the contribution of ZIP to HSA-SH reactivity increase was somewhat 267 
higher in defatted and lower FA content HSA/SA samples. Our finding that HSA-SH content and 268 
reactivity (and therefore HSA antioxidant properties) was changed in HSA/antipsychotic 269 
complexes (especially with ZIP) and that it can be modulated by FAs and concentration of drugs 270 
could be a useful additional factor in the choice and doses of these medicaments in the patients' 271 
treatment.  272 
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All described variations of the tested parameters are presumably a result of the different 273 
defatted HSA or HSA/SA complex conformation perturbations upon CLZ or ZIP binding. 274 
Indeed, the decrease of intrinsic protein fluorescence (Trp214 residue excitation) was noticeable 275 
in CLZ or ZIP-containing mixtures compared to the defatted HSA and HSA/SA samples without 276 
drugs. As expected, the intensity of fluorescence quenching at emission maximum was higher in 277 
HSA complexes with CLZ than with ZIP, in view of CLZ binding in the immediate vicinity of 278 
the fluorophore. ZIP binds distant from Trp214 fluorophore, therefore producing a lower then 279 
CLZ protein fluorescence quenching. On the other hand, the binding of ZIP near Cys34 residue 280 
causes a conformational change that positively affects the reactivity of this thiol group.  281 
The finding that plasma FAs content is significantly increased in schizophrenic patients 282 
due to the energy metabolic dysfunction [15,16] prompted us to quantify the influence of the 283 
formation of HSA/SA complexes on CLZ and ZIP binding. The observed binding constants 284 
ranged from 0.25 to 1.90×104 M−1, suggesting moderate binding of antipsychotics to HSA. The 285 
Ka value obtained for defatted HSA/CLZ complex (1.9×10
4 M−1) corresponds to previously 286 
reported [36]. The observed reduction in binding affinities of CLZ and ZIP to HSA that 287 
paralleled increased SA-complex content is presumably the consequence of the overlapping of 288 
their binding sites. Primary high-affinity sites of HSA for FAs are numbered as 2, 4 and 5. The 289 
secondary sites with moderate affinity for FAs binding correspond to sites 1, 3, 6 and 7 [37]. 290 
Sudlow I binding site for CLZ in subdomain IIA overlaps with FAs binding site 7, whereas 291 
binding site for ZIP located in IB subdomain overlaps with FA site 1 [12,14]. Our results suggest 292 
that, with increasing concentration of FAs bound to serum albumin, the availability of binding 293 
sites and the overall affinity for tested antipsychotics decreases. With increased SA binding, the 294 
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estimated number of binding sites for CLZ is reduced from 0.792 to 0.592 and from 0.786 to 295 
0.545 for ZIP. The observed effect is most likely due to cooperative conformational changes in 296 
the flexible native structure of serum albumins induced by competitive binding of FAs and drugs 297 
[38,39].   298 
These results open interesting questions pertinent to pharmacological and toxicological 299 
properties of these drugs in clinical settings. One is the actual drug concentration in the 300 
circulation of chronically treated patients since higher binding of FAs to HSA could influence 301 
their target sites bioavailability. The study presented here is, to the best of our knowledge, the 302 
first quantitative characterization of ZIP binding to HSA, with measured Ka value for defatted 303 
HSA/ZIP complex of 0.95×104 M−1 at 37°C.  304 
5. Conclusions 305 
The free plasma albumin-thiol group content plays a particularly important role in the 306 
antioxidant defense system. In this study, we report a finding that 4 weeks treatment of rats with 307 
CLZ significantly reduced total plasma thiols and albumin-SH content compared to the controls. 308 
Surprisingly, treatment of rats with another commonly used antipsychotic, ZIP, leads to an 309 
opposite effect on albumin-SH level. We found that both drugs altered the Cys34 thiol group 310 
content and reactivity which have been modulated by the SA content in protein complexes. 311 
Reactivity is increased upon CLZ, and especially upon ZIP binding to HSA complexes with 312 
lower SA levels which are present under physiological condition. This may have a positive effect 313 
on an overall antioxidant status, in particular with ZIP which increased plasma albumin-SH 314 
content in vitro as well. Compensatory increase in the free thiol group protein reactivity is a 315 
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possible mechanism for preserving the total thiols plasma content in vivo. When the number of 316 
SA molecules bound per molecule of HSA is increased to higher values more typical for 317 
schizophrenia, CLZ and ZIP binding is reduced. In contrast to CLZ, a positive effect of ZIP on 318 
the reactivity of HSA-SH group prevails. The observed differences could be explained by 319 
different binding properties of drugs to serum albumin, i.e. specificity of conformational protein 320 
changes induced by cooperative FAs and antipsychotics bindings. Taken together, our results 321 
suggest that, in contrast to CLZ, ZIP may have an additional beneficial therapeutic effect by 322 
contribution to plasma thiols homeostasis.   323 
Conflicts of Interest 324 
The authors declare no conflict of interest. 325 
Acknowledgment 326 
This work was supported by the Ministry of Education, Science and Technological Development 327 
of Serbia (Grants No. 172049 and 173014); and the EU's Horizon 2020 research and innovation 328 
program under grant agreement No. 810752. The EC does not share responsibility for the content 329 
of the article. 330 
References 331 
[1] K.R. Patel, J. Cherian, K. Gohil, D. Atkinson. Schizophrenia: overview and treatment 332 
options. P. T. 39 (2014) 638-645.  333 
[2] G. Remington. Alterations of dopamine and serotonin transmission in schizophrenia. Prog. 334 
Brain Res. 172 (2008) 117-140.  https://doi.org/10.1016/S0079-6123(08)00906-0 335 
17 
 
[3] M. Bošković, T. Vovk, B. Kores Plesničar, I. Grabnar. Oxidative Stress in Schizophrenia. 336 
Curr. Neuropharmacol. 9 (2011) 301-312. https://doi.org/10.2174/157015911795596595 337 
[4] M. Koga, A.V. Serritella, A. Sawa, T.W. Sedlak. Implications for reactive oxygen species in 338 
schizophrenia pathogenesis. Schizophr. Res. 176 (2016) 52-71. 339 
https://doi.org/10.1016/j.schres.2015.06.022 340 
[5] R.R. Reddy, M. Keshavan, J.K. Yao. Reduced plasma antioxidants in first-episode patients 341 
with schizophrenia. Schizophr. Res. 62 (2003) 205-212. https://doi.org/10.1016/S0920-342 
9964(02)00407-3 343 
[6] H.S. Dahake, S. Ghangle, J. Warade, Y. Pawade, G.S. Kansara. Study of nonenzymatic 344 
antioxidants in schizophrenic patients. Intern. J. Res. Med. Sci. 4 (2016) 3768-3772. 345 
http://dx.doi.org/10.18203/2320-6012.ijrms20162604 346 
[7] T.L. Huang, C.W. Liou, T.K. Lin. Serum thiobarbituric acid-reactive substances and free 347 
thiol levels in schizophrenia patients: Effects of antipsychotic drugs. Psychiatry Res. 177 348 
(2010) 18-21. https://doi.org/10.1016/j.psychres.2009.01.017 349 
[8] A. Ciobica, M. Padurariu, I. Dobrin, C. Stefanescu, R. Dobrin. Oxidative stress in 350 
schizophrenia - focusing on the main markers. Psychiatr. Danub. 23 (2011) 237-245. 351 
[9] M. Taverna, A.L. Marie, J.P. Mira, B. Guidet. Specific antioxidant properties of human 352 
serum albumin. Ann. Intensive Care 3 (2013) 4. https://doi.org/10.1186/2110-5820-3-4 353 
[10] L. Turell, R. Radi, B. Alvarez. The thiol pool in human plasma: The central contribution of 354 




[11] A.A. Bhattacharya, T. Grüne, S. Curry. Crystallographic analysis reveals common modes of 357 
binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol. 303 358 
(2000) 721-732. https://doi.org/10.1006/jmbi.2000.4158 359 
[12] M. Fasano, S. Curry, E. Terreno, M. Galliano, G. Fanali, P. Narciso, S. Notari, P. Ascenzi. 360 
The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57 361 
(2005) 787-796. https://doi.org/10.1080/15216540500404093 362 
[13] D.P. Cistola, D.M. Small. Fatty acid distribution in systems modeling the normal and 363 
diabetic human circulation. A 13C nuclear magnetic resonance study. J. Clin. Invest. 87 364 
(1991) 1431-1441. https://doi.org/10.1172/JCI115149 365 
[14] F. Zsila. Subdomain IB Is the Third Major Drug Binding Region of Human Serum 366 
Albumin: Toward the Three-Sites Model. Mol. Pharm. 10 (2013) 1668-1682. 367 
https://doi.org/10.1021/mp400027q 368 
[15] M. Orešič, J. Tang, T. Seppänen-Laakso, I. Mattila, S.E. Saarni, S.I. Saarni, J. Lönnqvist, 369 
M. Sysi-Aho, T. Hyötyläinen, J. Perälä, J. Suvisaari. Metabolome in schizophrenia and other 370 
psychotic disorders: a general population-based study. Genome Med. 3 (2011) 19. 371 
https://doi.org/10.1186/gm233 372 
[16] X. Yang, L. Sun, A. Zhao, X. Hu, Y. Qing, J. Jiang, C. Yang, T. Xu, P. Wang, J. Liu, J. 373 
Zhang, L. He, W. Jia, C. Wan. Serum fatty acid patterns in patients with schizophrenia: a 374 
targeted metabonomics study. Transl. Psychiatry 7 (2017) e1176. 375 
https://doi.org/10.1038/tp.2017.152 376 
[17] A. Nikolić-Kokić, N. Tatalović, J. Nestorov, M. Mijović, A. Mijusković, M. Miler, Z. 377 
Oreščanin-Dušić, M. Nikolić, V. Milošević, D. Blagojević, M. Spasić, Č. Miljević. 378 
19 
 
Clozapine, ziprasidone, and sertindole-induced morphological changes in the rat heart and 379 
their relationship to antioxidant enzymes function. J. Toxicol. Environ. Health A 81 (2018) 380 
844-853. https://doi.org/10.1080/15287394.2018.1495587 381 
[18] M.A. Raggi, R. Mandrioli, C. Sabbioni, V. Pucci. Atypical antipsychotics: 382 
pharmacokinetics, therapeutic drug monitoring, and pharmacological interactions, Curr. 383 
Med. Chem. 11 (2004) 279-96. https://doi.org/10.2174/0929867043456089 384 
[19] V.B. Jovanović, A.Z. Penezić-Romanjuk, I.D. Pavićević, J.M. Aćimović, L.M. Mandić. 385 
Improving the reliability of human serum albumin-thiol group determination. Anal. 386 
Biochem. 439 (2013) 17-22. https://doi.org/10.1016/j.ab.2013.03.033 387 
[20] H.W. Robinson, C.G. Hogden. The biuret reaction in the determination of serum proteins. 1. 388 
A study of the conditions necessary for the production of a stable color which bears a 389 
quantitative relationship to the protein concentration. J. Biol. Chem. 135 (1940) 707-725. 390 
[21] B.T. Dumas, W.A. Watson, H.G. Biggs. Albumin standards and the measurement of serum 391 
albumin with bromcresol green. Clin. Chim. Acta 258 (1997) 21-30. 392 
[22] R. Chen. Removal of Fatty Acids from Serum Albumin by Charcoal Treatment. J. Biol. 393 
Chem. 242 (1967) 173-181. 394 
[23] A.Z. Penezić, V.B. Jovanović, I.D. Pavićević, J.M. Aćimović, L.M. Mandić. HSA 395 
carbonylation with methylglyoxal and the binding/release of copper (II) ions. Metallomics 7 396 
(2015) 1431-1438. https://doi.org/10.1039/c5mt00159e 397 
[24] G. Bulaj, T. Kortemme, D.P. Goldenberg. Ionization-reactivity relationships for cysteine 398 




[25] I.D. Pavićević, V.B. Jovanović, M.M. Takić, A.Z. Penezić, J.M. Aćimović, L.M. Mandić. 401 
Fatty acids binding to human serum albumin: Changes of reactivity and glycation level of 402 
Cysteine-34 free thiol group with methylglyoxal. Chem. Biol. Interact. 224 (2014) 42-50. 403 
https://doi.org/10.1016/j.cbi.2014.10.008 404 
[26] M. Van de Weert, L. Stella. Fluorescence quenching and ligand binding: A critical 405 
discussion of a popular methodology. J. Mol. Struct. 998 (2011) 144-150. 406 
https://doi.org/10.1016/j.molstruc.2011.05.023 407 
[27] J.R. Lakowicz. Quenching of Fluorescence. In: J.R. Lakowicz (Ed.), Principles of 408 
Fluorescence Spectroscopy, 3rd ed., Springer: New York, 2006, pp. 277-330. 409 
[28] S. Bi, L. Ding, Y. Tian, D. Song, X. Zhou, X. Liu, H. Zhang. Investigation of the interaction 410 
between flavonoids and human serum albumin. J. Mol. Struct. 703 (2004) 37-45. 411 
https://doi.org/10.1016/j.molstruc.2004.05.026 412 
[29] Q. Li, W. Yang, L. Qu, H. Qi, Y. Huang, Z. Zhang. Interaction of warfarin with human 413 
serum albumin and effect of ferulic acid on the binding. J. Spectr. 2014 (2014) 1-7. 414 
http://dx.doi.org/10.1155/2014/834501 415 
[30] E. Walker, K. Tessner. Schizophrenia. Perspect. Psychol. Sci. 3 (2008) 30-37. 416 
https://doi.org/10.1111%2Fj.1745-6916.2008.00059.x 417 
[31] F.E. Emiliani, T.W. Sedlak, A. Sawa. Oxidative stress and schizophrenia: recent 418 




[32] N. Todorović, D. Filipović. The antidepressant- and anxiolytic-like effects of fluoxetine and 421 
clozapine in chronically isolated rats involve inhibition of hippocampal TNF-α. Pharmacol. 422 
Biochem. Behav. 163 (2017) 57-65. https://doi.org/10.1016/j.pbb.2017.10.006 423 
[33] M.M. Takić, V.B. Jovanović, I.D. Pavićević, T.N. Uzelac, J.M. Aćimović, D.K. Ristić-424 
Medić, L.M. Mandić. Binding of enterolactone and enterodiol to human serum albumin: 425 
increase of cysteine-34 thiol group reactivity. Food Funct. 7 (2016) 1217-1226. 426 
https://doi.org/10.1039/c5fo01346a 427 
[34] V.B. Jovanović, I.D. Pavićević, M.M. Takić, A.Z. Penezić-Romanjuk, J.M. Aćimović, L.M. 428 
Mandić. The influence of fatty acids on determination of human serum albumin thiol group. 429 
Anal. Biochem. 448 (2014) 50-57. https://doi.org/10.1016/j.ab.2013.11.030 430 
[35] M.J. Torres, L. Turell, H. Botti, L. Antmann, S. Carballal, G. Ferrer-Sueta, R. Radi, B. 431 
Alvarez. Modulation of the reactivity of the thiol of human serum albumin and its sulfenic 432 
derivative by fatty acids. Arch. Biochem. Biophys. 521 (2012) 102-110. 433 
https://doi.org/10.1016/j.abb.2012.03.011 434 
[36] X. Wu, J. Liu, Q. Wang, W. Xue, X. Yao, Y. Zhang, J. Jin. Spectroscopic and molecular 435 
modeling evidence of clozapine binding to human serum albumin at subdomain IIA. 436 
Spectrochim. Acta A Mol. Biomol. Spectrosc. 79 (2011) 1202-1209. 437 
https://doi.org/10.1016/j.saa.2011.04.043 438 
[37] G.J. van der Vusse. Albumin as fatty acid transporter. Drug Metab. Pharmacokinet. 24 439 
(2009) 300-307. https://doi.org/10.2133/dmpk.24.300 440 
22 
 
[38] J. Reichenwallner, D. Hinderberger. Using bound fatty acids to disclose the functional 441 
structure of serum albumin. Biochim. Biophys. Acta 1830 (2013) 5382-5393. 442 
https://doi.org/10.1016/j.bbagen.2013.04.031 443 
[39] A. Tramarin, D. Tedesco, M. Naldi, M. Baldassarre, C. Bertucci, M. Bartolini. New insights 444 
into the altered binding capacity of pharmaceutical-grade human serum albumin: site-445 
specific binding studies by induced circular dichroism spectroscopy. J. Pharm. Biomed. 446 















Figure Legends 460 
Fig. 1. Chemical structure of clozapine (left) and ziprasidone. 461 
Fig. 2. Changes of HSA-SH group content (%) in the complexes of defatted HSA and HSA/SA 462 
samples after CLZ or ZIP binding in comparison to the drug-free complexes. HSA to drug ratios 463 
were 1:0.5, 1:1.5 and 1:2. Values are expressed as the mean value (±SD) of three determinations. 464 
An asterisk indicates a significant difference (P<0.05; t-test) in the HSA-SH group content of 465 
each HSA/ZIP complexes (colon) in comparison to corresponding HSA/SA complexes. CLZ, 466 
Clozapine; ZIP, Ziprasidone; FAs, Fatty acids; HSA, Human serum albumin; HSA-SH, Cys34 467 
free thiol group of HSA; SA, Stearic acid; HSA/SA, HSA in complex with stearic acid.  468 
Fig. 3. Linear models of pseudo-first-order reaction kinetics of the Cys34 thiol group of defatted 469 
HSA and HSA/SA complexes (of protein to FA molar ratios 1:1, 1:2, 1:3 and 1:4) with DTNB, 470 
obtained after binding of (a) CLZ (in molar ratio HSA/CLZ 1:2) and (b) ZIP (HSA/ZIP 1:2). 471 
CLZ, Clozapine; ZIP, Ziprasidone; FAs, Fatty acids; HSA, Human serum albumin; HSA-SH, 472 
Cys34 free thiol group of HSA; SA, Stearic acid; HSA/SA, HSA in complex with stearic acid; 473 
HSA/CLZ and HSA/ZIP, HSA in complex with clozapine and ziprasidone, respectively; DTNB, 474 
5,5′-Dithiobis-(2-nitrobenzoic acid). 475 
Fig. 4. Singular contributions (Δ k`) of antipsychotics to decrease/increase in reactivity of the 476 
Cys34 group of defatted HSA and HSA/SA (molar protein to FA ratios 1:1, 1:2, 1:3 and 1:4) 477 
samples compared to the controls. CLZ, Clozapine; ZIP, Ziprasidone; FAs, Fatty acids; HSA, 478 
Human serum albumin; SA, Stearic acid; HSA/SA, HSA in complex with stearic acid.  479 
24 
 
Fig. 5. Fluorescence emission spectra of 1 μM defatted HSA and HSA/SA (protein to FA molar 480 
ratio 1:2) samples before and after the addition of CLZ or ZIP (2.0 μM), at 37 °C and pH 7.4, 481 
after excitation at 295 nm. CLZ, Clozapine; ZIP, Ziprasidone; FAs, Fatty acids; HSA, Human 482 

















Table 1  498 
Plasma biochemical values after 4-weeks treatment of rats with clozapine (CLZ; 45 mg/kg/day) 499 
and ziprasidone (ZIP; 20 mg/kg/day), and in the control group. The data are expressed as the 500 
mean value (± SD) of three measurements. 501 
Parameter (number of animals) Control (8) CLZ (8) ZIP (8) 
Total proteins (g/L) 70.7 ± 5.7 58.1 ± 5.3* 60.5 ± 1.7* 
Albumin (g/L) 33.0 ± 5.5 22.0 ± 2.8* 23.3 ± 2.7* 
Total thiols (mM) 0.188 ± 0.041 0.109 ± 0.011* 0.157 ± 0.027 
Albumin-SH (M –SH/M albumin) 0.215 ± 0.060 0.169 ± 0.035* 0.243 ± 0.045* 











Table 2  511 
Pseudo-first-order rate constants (k'), as the measure of Cys34-SH group reactivity with DTNB 512 
in defatted HSA and HSA/SA samples (protein to SA molar ratios: 1:1, 1:2, 1:3 and 1:4), after 513 
CLZ and ZIP binding to HSA samples (protein to drug molar ratios of 1:0.5, 1:1.5 and 1:2). k' 514 
values are expressed as the mean (±SD) of three determinations.  515 
k' x 10-3 (s-1) 
 defatted HSA HSA/SA 1:1 HSA/SA 1:2 HSA/SA 1:3 HSA/SA 1:4 
Drug free 18.3 ± 0.6 22.8 ± 0.6 25.2 ± 0.7 28.3 ± 1.1 32.7 ± 1.1 
0.5 
CLZ    1.5 
2.0 
19.2 ± 0.9 
20.2 ± 0.7* 
20.4 ± 0.3* 
23.9 ± 0.5 
24.7 ± 0.1* 
25.7 ± 0.2* 
25.5 ± 0.2 
26.6 ± 0.6 
27.9 ± 0.3* 
23.8 ± 0.5* 
24.3 ± 0.5* 
25.8 ± 0.4* 
27.2 ± 0.4* 
29.6 ± 0.1* 
30.1 ± 0.7* 
0.5 
ZIP    1.5 
2.0 
24.0 ± 0.7* 
29.1 ± 0.5* 
29.6 ± 0.3* 
23.9 ± 0.5 
29.3 ± 0.2* 
30.6 ± 0.6* 
26.2 ± 0.5 
28.7 ± 0.7* 
30.8 ± 0.5* 
29.1 ± 0.5 
32.1 ± 0.3* 
33.3 ± 0.5* 
35.1 ± 0.1* 
38.4 ± 0.2* 
38.6 ± 0.7* 
* P<0.05 (t-test) in comparison to corresponding defatted HSA and HSA/SA samples without 516 
drugs. CLZ, Clozapine; ZIP, Ziprasidone; Human serum albumin; SA, Stearic acid; HSA/SA, 517 






Table 3  522 
Stern-Volmer quenching constants (KSV), fluorescence quenching rate constants (kq), binding 523 
constants (Ka) and number of binding sites (n) for CLZ and ZIP binding to either defatted HSA 524 
or HSA/SA samples (molar protein to SA ratios 1:1, 1:2, 1:3 and 1:4), at 37°C and pH 7.4. KSV, 525 
Ka and n values are expressed as the mean (± SD) of two independent experiments, each 526 
















        Defatted HSA 2.89 ± 0.078 2.89 1.90 ± 0.032  0.792 ± 0.013 
CLZ          HSA/SA 1:1 
HSA/SA 1:2 
HSA/SA 1:3 
2.48 ± 0.045 
2.45 ± 0.064 




1.73 ± 0.050 
1.20 ± 0.048 
0.99 ± 0.032 
0.789 ± 0.023 
0.690 ± 0.022 
0.666 ± 0.021 
HSA/SA 1:4 2.34 ± 0.072 2.34 0.82 ± 0.019 0.592 ± 0.014 
Defatted HSA 2.18 ± 0.040 2.18 0.95 ± 0.015 0.786 ± 0.013 
ZIP            HSA/SA 1:1 
HSA/SA 1:2 
HSA/SA 1:3 
1.90 ± 0.028 
1.54 ± 0.034 




0.62 ± 0.021 
0.38 ± 0.016 
0.29 ± 0.014 
0.661 ± 0.017 
0.653 ± 0.018 
0.572 ± 0.024 
HSA/SA 1:4 1.02 ± 0.021 1.02 0.25 ± 0.005 0.545 ± 0.012 
CLZ, Clozapine; ZIP, Ziprasidone; HSA, Human serum albumin; SA, Stearic acid; HSA/SA, 528 
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